FAQ on Soligenix Inc.'s Progress in Rare Disease Therapeutics
Summary
What is Soligenix Inc. known for?
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, including its HyBryte(TM) platform for cutaneous T-cell lymphoma.
Why is Soligenix’s work important?
With over 30 million Americans living with rare conditions, many lacking FDA-approved therapies, Soligenix’s innovative treatments like HyBryte(TM) represent a promising solution for underserved populations, particularly aging adults.
What is HyBryte(TM)?
HyBryte(TM) is Soligenix’s novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, a rare skin cancer affecting older adults.
How far along is Soligenix in developing HyBryte(TM)?
Soligenix has successfully completed the second Phase 3 study of HyBryte(TM) and is moving toward seeking regulatory approvals to support potential commercialization worldwide.
What other diseases is Soligenix targeting?
Beyond cutaneous T-cell lymphoma, Soligenix is expanding its synthetic hypericin into psoriasis, developing treatments for inflammatory diseases, and working on vaccine programs for ricin toxin, filoviruses, and COVID-19.
Who funds Soligenix’s vaccine programs?
Soligenix’s vaccine programs, including those for ricin toxin, filoviruses, and COVID-19, have been supported with government grants and contract funding from NIAID, DTRA, and BARDA.
Where can I find more information about Soligenix?
For further information, visit Soligenix’s website at www.Soligenix.com or check the latest news and updates relating to SNGX in the company’s newsroom at https://ibn.fm/SNGX.
What is the significance of Soligenix’s domestic manufacturing of HyBryte’s active ingredient?
The successful domestic manufacturing of HyBryte’s active ingredient advances Soligenix’s mission to serve the underserved demographic of aging adults with rare diseases through innovative, U.S.-based therapies.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 136151